EVUSHELD 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3 
amended 
on 
II/0013 
C.I.11.b - Introduction of, or change(s) to, the
26/10/2023 
n/a 
obligations and conditions of a marketing
authorisation, including the RMP - Implementation of
change(s) which require to be further substantiated
by new additional data to be submitted by the MAH
where significant assessment is required
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
II/0009/G 
Grouped application comprising two type II 
12/10/2023 
n/a 
SmPC 
SmPC new text 
variations (REC 23) as follows: 
C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the 
SmPC in order to update efficacy and satefy 
information based on final results from study TACKLE 
(D8851C00001). 
C.I.4 - Update of sections 4.4, 4.8, 5.1 and 5.2 of 
the SmPC in order to update efficacy and safety 
information based on final results from studies 
PROVENT (D8850C00002) and STORM CHASER 
(D8850C00003). In addition, the MAH took the 
opportunity to add some editorial changes.  The RMP 
version 4.2 is also updated. 
The PK modelling ,efficacy and safety information included 
in the SmPC for Evusheld is updated considering the final 
data analysis coming from PROVENT, STORM CHASER and 
TACKLE studies. 
For more information, please refer to the Summary of 
Product Characteristics. 
IAIN/0015 
A.5.a - Administrative change - Change in the name 
02/10/2023 
and/or address of a manufacturer/importer 
responsible for batch release 
Annex II and 
PL 
PSUSA/10992
Periodic Safety Update EU Single assessment - 
22/06/2023 
16/08/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202211 
tixagevimab / cilgavimab (Evusheld) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10992/202211. 
IB/0012 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
31/07/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0011 
A.5.b - Administrative change - Change in the name 
05/06/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0007/G 
This was an application for a group of variations. 
30/03/2023 
16/08/2023 
SmPC 
The SmPC section 6.3. has been updated as follows:  
Unopened vial 
2 years 
B.II.f.1.b.4 - Stability of FP - Extension of the shelf 
life of the finished product - Based on extrapolation 
of stability data not in accordance with ICH/VICH 
guidelines 
B.II.f.1.b.4 - Stability of FP - Extension of the shelf 
life of the finished product - Based on extrapolation 
of stability data not in accordance with ICH/VICH 
guidelines 
II/0006/G 
This was an application for a group of variations. 
16/02/2023 
n/a 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
PSUSA/10992
Periodic Safety Update EU Single assessment - 
01/12/2022 
n/a 
PRAC Recommendation - maintenance 
/202205 
tixagevimab / cilgavimab (Evusheld) 
IB/0005/G 
This was an application for a group of variations. 
21/11/2022 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
II/0001 
C.I.6.a - Change(s) to therapeutic indication(s) - 
15/09/2022 
16/09/2022 
SmPC and PL 
Extension of indication to include treatment of adults and 
Addition of a new therapeutic indication or 
modification of an approved one 
II/0002/G 
This was an application for a group of variations. 
15/09/2022 
16/09/2022 
SmPC and 
Annex II 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
adolescents (aged 12 years and older weighing at least 40 
kg) with COVID-19, who do not require supplemental 
oxygen and are at increased risk of progressing to severe 
COVID-19. As a consequence, sections 4.1, 4.2, 4.4,4.8, 
4.9, 5.1, 5.2 ,6.3, 6.6 of the SmPC are updated. The 
Package Leaflet is updated in accordance. In addition, the 
MAH took the opportunity to make some editorial changes. 
Version 2.0 of the RMP has also been submitted. 
Please refer to Scientific Discussion - 
“Evusheld/H/C/005788/II/0001” 
Page 4/5 
 
 
 
 
 
 
 
 
 
material [-] used in the manufacture of a 
biological/immunological product 
Page 5/5 
 
 
 
 
 
 
 
